Springhouse

Recent papers from Springhouse

1. Bispecific antibodies that engage pIgR enrich in mucosa in cynomolgus monkeysmAbs · 2026
2. Identification of a novel dependency between PRMT5 and APC-LOF in preclinical models of FAP diseaseCommunications Biology · 2026
3. Ring Currents in Open-Shell Condensed Benzenoid Homologues of Some Extended Clar’s GobletsThe Journal of Physical Chemistry A · 2026
4. Where to Draw the LineQueue · 2026
5. Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) with Psoriatic Disease: Exploratory Assessments from a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)The Journal of Rheumatology · 2026
6. Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity with Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results from ApexThe Journal of Rheumatology · 2026
7. Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSBlood Advances · 2026
8. New Approach Methods in Genetic ToxicologyEnvironmental and Molecular Mutagenesis · 2026
9. Real-time tomography of stress corrosion cracking on stainless steel by an in-situ corrosion tensile testCorrosion Communications · 2026
10. Matching-Adjusted Indirect Comparisons of Gemcitabine Intravesical System vs Novel Agents in Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder CancerJU Open Plus · 2026
11. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trialChinese Medical Journal · 2026
12. Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONEBlood Advances · 2026
13. IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease.2026
14. Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.2026
15. Spontaneously self-assembled micelles from poly(ethylene glycol)- b-poly(ɛ-caprolactone-co-trimethylene carbonate) for drug solubilization˜Die œPharmazie · 2008
16. Genomic analyses implicate hormonal and metabolic dysregulation in polycystic ovary syndromeNature Genetics · 2026
17. Abstract CT216: OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancerCancer Research · 2026
18. Abstract LB474: Impact of first-line (1L) amivantamab-lazertinib vs osimertinib on second-line (2L) progression-free survival (PFS)Cancer Research · 2026
19. Abstract CT050: Preliminary clinical results of TAVO412, an anti-EGFR/cMET/VEGF multispecific antibody, in patients with advanced or metastatic solid tumorsCancer Research · 2026
20. Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancerCancer Research · 2026